← Eichor
Condition: Advanced Clear Renal Cell Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Clear Renal Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Phase 1 · 7 location(s) · Sairopa B.V. · NCT05856981Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Ce
Phase 1 · 11 location(s) · Neomorph, Inc · NCT07300241VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Phase 2 · 1 location(s) · Mayo Clinic · NCT07510334A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Phase 2 · 2 location(s) · Stephanie Berg · NCT07123090Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05155033Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica
Phase 1/Phase 2 · 128 location(s) · Pfizer · NCT07227415Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Phase 3 · 5 location(s) · Telix Pharmaceuticals (Innovations) Pty Limited · NCT07197580Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Phase 1 · 122 location(s) · Exelixis · NCT05176483A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres
Phase 1 · 5 location(s) · Novelty Nobility, Inc. · NCT06805825Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT07564232Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
Phase 3 · 41 location(s) · SWOG Cancer Research Network · NCT07383441Imaging of Solid Tumors Using 18F-TRX
Phase 1 · 1 location(s) · Rahul Aggarwal · NCT06942104Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell
Phase 1/Phase 2 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT06866262A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06699602Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Phase 1/Phase 2 · 5 location(s) · Oncorena AB · NCT05287945A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced
Phase 2 · 6 location(s) · M.D. Anderson Cancer Center · NCT06708949Agnostic Therapy in Rare Solid Tumors
Phase 2 · 8 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06638931IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
Phase 1 · 1 location(s) · Grit Biotechnology · NCT06819293CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Phase 1 · 1 location(s) · Osel, Inc. · NCT06399419A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With C
Phase 1 · 41 location(s) · Genentech, Inc. · NCT05581004A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · ITM Oncologics GmbH · NCT05706129A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Phase 1/Phase 2 · 4 location(s) · Cancer Research UK · NCT06380816Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma
Phase 1/Phase 2 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT07097935A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 1 · 9 location(s) · Bristol-Myers Squibb · NCT07195682A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Pliant Therapeutics, Inc. · NCT06270706A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal
Phase 2 · 2 location(s) · Brian Rini · NCT07188896Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Phase 2 · 6 location(s) · Vanderbilt-Ingram Cancer Center · NCT05361720
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.